<article article-type="brief-report" dtd-version="1.4" xml:lang="en"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Ther</journal-id><journal-id journal-id-type="iso-abbrev">Mol Ther</journal-id><journal-id journal-id-type="pmc-domain-id">902</journal-id><journal-id journal-id-type="pmc-domain">molther</journal-id><journal-title-group><journal-title>Molecular Therapy</journal-title></journal-title-group><issn pub-type="ppub">1525-0016</issn><issn pub-type="epub">1525-0024</issn><publisher><publisher-name>American Society of Gene &amp; Cell Therapy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12925777</article-id><article-id pub-id-type="pmcid-ver">PMC12925777.1</article-id><article-id pub-id-type="pmcaid">12925777</article-id><article-id pub-id-type="pmcaiid">12925777</article-id><article-id pub-id-type="pmid">41047627</article-id><article-id pub-id-type="doi">10.1016/j.ymthe.2025.10.007</article-id><article-id pub-id-type="pii">S1525-0016(25)00828-7</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Real-world outcomes of delandistrogene moxeparvovec gene therapy: Motor outcomes and emerging safety concerns</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Keselman</surname><given-names initials="DJ">Dennis J.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="fn2">10</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Small</surname><given-names initials="JC">Juliana C.</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Seneviratne</surname><given-names initials="T">Tiffany</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>McCague</surname><given-names initials="S">Sarah</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Kaschak</surname><given-names initials="TL">Taylor L.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Yum</surname><given-names initials="SW">Sabrina W.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>O’Brien</surname><given-names initials="A">Andrea</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author" id="au8"><name name-style="western"><surname>Brandsema</surname><given-names initials="JF">John F.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author" id="au9"><name name-style="western"><surname>Diamond</surname><given-names initials="T">Tamir</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author" id="au10"><name name-style="western"><surname>Loomes</surname><given-names initials="KM">Kathleen M.</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author" id="au11"><name name-style="western"><surname>Lin</surname><given-names initials="KY">Kimberly Y.</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author" id="au12"><name name-style="western"><surname>Wittlieb-Weber</surname><given-names initials="CA">Carol A.</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author" id="au13"><name name-style="western"><surname>Mayer</surname><given-names initials="OH">Oscar H.</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author" id="au14"><name name-style="western"><surname>Daniel</surname><given-names initials="SG">Scott G.</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author" id="au15"><name name-style="western"><surname>Waldman</surname><given-names initials="AT">Amy T.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author" id="au16"><name name-style="western"><surname>Samelson-Jones</surname><given-names initials="BJ">Benjamin J.</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author" id="au17"><name name-style="western"><surname>Matesanz</surname><given-names initials="SE">Susan E.</given-names></name><email>matesanzs@chop.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="fn1">9</xref><xref ref-type="corresp" rid="cor1">∗</xref></contrib><contrib contrib-type="author" id="au18"><name name-style="western"><surname>George</surname><given-names initials="LA">Lindsey A.</given-names></name><email>georgel@chop.edu</email><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="fn1">9</xref><xref ref-type="corresp" rid="cor2">∗∗</xref></contrib><aff id="aff1"><label>1</label>Division of Neurology, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA</aff><aff id="aff2"><label>2</label>Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA</aff><aff id="aff3"><label>3</label>Clinical In Vivo Gene Therapy, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA</aff><aff id="aff4"><label>4</label>Bioinformatics and Division of Gastroenterology, Hepatology and Nutrition, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA</aff><aff id="aff5"><label>5</label>Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA</aff><aff id="aff6"><label>6</label>Division of Cardiology, Cardiac Center, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA</aff><aff id="aff7"><label>7</label>Division of Pulmonology, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA</aff><aff id="aff8"><label>8</label>Division of Hematology, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA</aff></contrib-group><author-notes><corresp id="cor1"><label>∗</label>Corresponding author: Susan E. Matesanz, MD, Division of Neurology, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA. <email>matesanzs@chop.edu</email></corresp><corresp id="cor2"><label>∗∗</label>Corresponding author: Lindsey A. George, MD, Clinical In Vivo Gene Therapy, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA. <email>georgel@chop.edu</email></corresp><fn id="fn1"><label>9</label><p id="ntpara0010">These authors contributed equally</p></fn><fn id="fn2"><label>10</label><p id="ntpara0015">Present address: Division of Neurology, Boston Children’s Health Physicians and Department of Neurology, Westchester Medical Center at New York Medical College, Valhalla, NY, USA</p></fn></author-notes><pub-date pub-type="ppub"><day>07</day><month>1</month><year>2026</year></pub-date><pub-date pub-type="epub"><day>04</day><month>10</month><year>2025</year></pub-date><volume>34</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">508105</issue-id><fpage>123</fpage><lpage>130</lpage><history><date date-type="received"><day>12</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>2</day><month>10</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>04</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>23</day><month>02</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-02-25 13:25:12.750"><day>25</day><month>02</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>© 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref content-type="ccbyncndlicense" specific-use="textmining" xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="main.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/><abstract id="abs0010"><p>Delandistrogene moxeparvovec is currently the only commercially approved gene therapy for Duchenne muscular dystrophy (DMD). Herein, we report real-world data of 11 ambulatory patients with DMD, ages 4–6, treated with commercial delandistrogene moxeparvovec. Patients were prospectively and uniformly monitored for 1 year post-gene transfer for safety and motor outcomes. Nine patients experienced 15 treatment-related toxicities, and 4 required escalation of corticosteroids. Side effects included gastrointestinal symptoms (<italic toggle="yes">n</italic> = 7), liver enzyme abnormalities (<italic toggle="yes">n</italic> = 4), acute liver injury (<italic toggle="yes">n</italic> = 2), and troponin I elevations (<italic toggle="yes">n</italic> = 3). In both patients with acute liver injury, troponin I elevations occurred in close temporal association beginning 8–9 weeks post-gene transfer and were responsive to corticosteroids. The clinical courses of these two patients were at least partially consistent with a cellular immune response to the adeno-associated viral vector (AAV) capsid. Troponin I elevations were asymptomatic and without acute functional changes on echocardiogram. The cohort had improvements in year 1 motor function assessments relative to baseline, including a statistically significant median 4-point increase in North Star Ambulatory Assessment score; however, important confounding factors, e.g., baseline corticosteroid use, limit interpretation and will be important to control for in future real-world datasets. Additional follow-up is required to determine long-term safety and motor outcomes, with unclear generalizability of our results.</p></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><fig id="undfig1" orientation="portrait" position="anchor"><graphic orientation="portrait" position="float" xlink:href="fx1.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig></abstract><abstract abstract-type="teaser" id="abs0020"><p>Matesanz and colleagues report real-world data of 11 baseline ambulatory patients with Duchenne muscular dystrophy, ages 4–6, treated with commercial delandistrogene moxeparvovec. All patients demonstrated motor improvements at 1 year. Side effects occurred at higher rates than in trials but responded to corticosteroid intervention. The authors highlight the need for long-term data in commercially treated patients.</p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>AAV</kwd><kwd>DMD</kwd><kwd>delandistrogene moxeparvovec</kwd><kwd>real-world outcomes</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC-ND</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p id="p0010">Duchenne muscular dystrophy (DMD) is an X-linked neuromuscular disorder that affects 1 in 5,000 males.<xref ref-type="bibr" rid="bib1"><sup>1</sup></xref> It is caused by pathogenic variants in the <italic toggle="yes">DMD</italic> gene that encodes dystrophin—an intracellularly expressed protein essential to muscle cell membrane integrity.<xref ref-type="bibr" rid="bib1"><sup>1</sup></xref> Without dystrophin function, muscles undergo repeated injury with insufficient repair, resulting in loss of ambulation and premature death from cardio-pulmonary insufficiency at a median of 30 years.<xref ref-type="bibr" rid="bib1"><sup>1</sup></xref> Without curative treatments, there is significant interest in developing gene-based therapies. To overcome adeno-associated viral vector (AAV) packaging constraints (4.7 kb), multiple groups<xref ref-type="bibr" rid="bib2"><sup>2</sup></xref> developed micro-dystrophin transgenes aiming to convert the severe DMD phenotype to a milder form.<xref ref-type="bibr" rid="bib3"><sup>3</sup></xref></p><p id="p0015">Delandistrogene moxeparvovec (Elevidys; Sarepta Therapeutics) is the first US Food and Drug Administration (FDA)-approved gene therapy for DMD. The AAVrh74 vector encapsidates a micro-dystrophin transgene and MCKH7 promoter and is administered intravenously at a dose of 1.33 × 10<sup>14</sup> vg/kg.<xref ref-type="bibr" rid="bib4"><sup>4</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib5"><sup>5</sup></xref> Accelerated approval was granted in 2023 for children 4–5 years of age with DMD, excluding patients with exon 8 or 9 deletions.<xref ref-type="bibr" rid="bib6"><sup>6</sup></xref> Full approval for ambulatory patients ≥4 years was granted in 2024 with concurrent accelerated approval for non-ambulatory patients. The pivotal EMBARK trial enrolled patients with DMD ≥4 to &lt;8 years old on stable corticosteroid regimens with North Star Ambulatory Assessment (NSAA) total scores of &gt;16 to &lt;29 and a time to rise (TTR) &lt; 5 s.<xref ref-type="bibr" rid="bib5"><sup>5</sup></xref> The study did not meet the primary endpoint of significant NSAA improvement at 1 year, though multiple secondary motor outcome endpoints were achieved with a tolerable safety profile.</p><p id="p0020">Herein, we report real-world safety and motor outcome data of delandistrogene moxeparvovec therapy in 11 ambulatory 4- to 6-year-old patients with DMD. All patients demonstrated motor function improvements from baseline. Nine of 11 experienced side effects. The courses of the two patients with the most pronounced combined cardiac and hepatic toxicity were consistent with a cellular immune response<xref ref-type="bibr" rid="bib7"><sup>7</sup></xref> to the vector capsid, suggesting that this mechanism may underlie, at least in part, some observed short-term toxicities.</p></sec><sec id="sec2"><title>Results</title><p id="p0025">Eleven patients aged 4–6 years received delandistrogene moxeparvovec between August 2023 and June 2024 (<xref ref-type="table" rid="tbl1">Table 1</xref>). Nine of 11 patients did not meet EMBARK inclusion criteria<xref ref-type="bibr" rid="bib5"><sup>5</sup></xref> due to ≥1 of the following: low (3/11) or high (1/11) NSAA score, excess TTR (5/11), corticosteroid-naive status (6/11), prior exon-skipping therapy (2/11, stopped before gene transfer and not re-initiated), severe behavioral concerns (2/11), or medical comorbidities (1/11, feeding tube dependence) (<xref ref-type="table" rid="tbl1">Table 1</xref>). No patients had exon 1–17 or 59–71 <italic toggle="yes">DMD</italic> deletions, associated with increased risk of immune-mediated myositis.<xref ref-type="bibr" rid="bib8"><sup>8</sup></xref> All patients initiated or increased corticosteroids before gene transfer, per label recommendations.<table-wrap id="tbl1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline patient characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="2">Baseline characteristics</th><th colspan="12" rowspan="1">Patient ID<hr/></th></tr><tr><th colspan="1" rowspan="1">1</th><th colspan="1" rowspan="1">2</th><th colspan="1" rowspan="1">3</th><th colspan="1" rowspan="1">4</th><th colspan="1" rowspan="1">5</th><th colspan="1" rowspan="1">6</th><th colspan="1" rowspan="1">7</th><th colspan="1" rowspan="1">8</th><th colspan="1" rowspan="1">9</th><th colspan="1" rowspan="1">10</th><th colspan="1" rowspan="1">11</th><th colspan="1" rowspan="1">Cohort (<italic toggle="yes">n</italic> = 11)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Age, years, median (range)</td><td colspan="1" rowspan="1">5.9</td><td colspan="1" rowspan="1">6.1</td><td colspan="1" rowspan="1">5.0</td><td colspan="1" rowspan="1">5.9</td><td colspan="1" rowspan="1">5.2</td><td colspan="1" rowspan="1">5.9</td><td colspan="1" rowspan="1">5.2</td><td colspan="1" rowspan="1">4.2</td><td colspan="1" rowspan="1">4.5</td><td colspan="1" rowspan="1">5.9</td><td colspan="1" rowspan="1">4.3</td><td colspan="1" rowspan="1">5.30 (4.25–6.15)</td></tr><tr><td colspan="1" rowspan="1">ASD or ADHD, <italic toggle="yes">n</italic> (%)</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">6 (54.54)</td></tr><tr><td colspan="1" rowspan="1"> ASD</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">3 (27.27)</td></tr><tr><td colspan="1" rowspan="1"> ADHD</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">3 (27.27)</td></tr><tr><td colspan="1" rowspan="1">Left ventricle ejection fraction &lt; 55% or regional wall abnormalities, <italic toggle="yes">n</italic> (%)</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">0 (0)</td></tr><tr><td colspan="1" rowspan="1">Corticosteroid treatment,<xref ref-type="table-fn" rid="tblfn1">a</xref><italic toggle="yes">n</italic> (%)</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">5 (45.45)</td></tr><tr><td colspan="1" rowspan="1"> Prednisone/prednisolone</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">2 (40.00)</td></tr><tr><td colspan="1" rowspan="1"> Deflazacort</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">3 (60.00)</td></tr><tr><td colspan="1" rowspan="1">Time since corticosteroid treatment initiated, years</td><td colspan="1" rowspan="1">0.52</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">3.10</td><td colspan="1" rowspan="1">1.22</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">0.34</td><td colspan="1" rowspan="1">1.87</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">1.22</td></tr><tr><td colspan="1" rowspan="1">Exon-skipping therapy use, <italic toggle="yes">n</italic> (%)<xref ref-type="table-fn" rid="tblfn2">b</xref></td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">2 (18.18)</td></tr><tr><td colspan="1" rowspan="1">Pathogenic variant, <italic toggle="yes">n</italic> (%)</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td></tr><tr><td colspan="1" rowspan="1"> Large deletion</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">7 (64.64)</td></tr><tr><td colspan="1" rowspan="1"> Large duplication</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">0 (0)</td></tr><tr><td colspan="1" rowspan="1"> Small variant</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">4 (36.36)</td></tr><tr><td colspan="1" rowspan="1">  Nonsense variant</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">3 (27.27)</td></tr><tr><td colspan="1" rowspan="1">  Frameshift variant</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">1 (9.09)</td></tr><tr><td colspan="1" rowspan="1">  Intron variant</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">0 (0)</td></tr><tr><td colspan="1" rowspan="1">Motor function scores</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td></tr><tr><td colspan="1" rowspan="1"> NSAA total score, points, median (range)</td><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">30</td><td colspan="1" rowspan="1">28</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">25</td><td colspan="1" rowspan="1">26</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">17</td><td colspan="1" rowspan="1">20.00 (12–30)</td></tr><tr><td colspan="1" rowspan="1"> TTR, seconds, median (range)</td><td colspan="1" rowspan="1">5.5</td><td colspan="1" rowspan="1">14.2</td><td colspan="1" rowspan="1">14.7</td><td colspan="1" rowspan="1">1.9</td><td colspan="1" rowspan="1">2.5</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">2.9</td><td colspan="1" rowspan="1">4.4</td><td colspan="1" rowspan="1">4.5</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">7.3</td><td colspan="1" rowspan="1">4.45 (0.77–13.93)</td></tr><tr><td colspan="1" rowspan="1"> 10MWR, seconds, median (range)</td><td colspan="1" rowspan="1">5.8</td><td colspan="1" rowspan="1">7.5</td><td colspan="1" rowspan="1">7.0</td><td colspan="1" rowspan="1">3.4</td><td colspan="1" rowspan="1">4.1</td><td colspan="1" rowspan="1">6.7</td><td colspan="1" rowspan="1">5.0</td><td colspan="1" rowspan="1">4.3</td><td colspan="1" rowspan="1">6.4</td><td colspan="1" rowspan="1">5.5</td><td colspan="1" rowspan="1">6.4</td><td colspan="1" rowspan="1">5.80 (3.4–7.5)</td></tr><tr><td colspan="1" rowspan="1"> 4SC, seconds, median (range)</td><td colspan="1" rowspan="1">4.9</td><td colspan="1" rowspan="1">7.4</td><td colspan="1" rowspan="1">18.1</td><td colspan="1" rowspan="1">2.0</td><td colspan="1" rowspan="1">1.8</td><td colspan="1" rowspan="1">13.1</td><td colspan="1" rowspan="1">2.3</td><td colspan="1" rowspan="1">3.8</td><td colspan="1" rowspan="1">3.6</td><td colspan="1" rowspan="1">13.3</td><td colspan="1" rowspan="1">5.1</td><td colspan="1" rowspan="1">4.9 (1.84–18.14)</td></tr><tr><td colspan="1" rowspan="1"> 100MWR, seconds, median (range)</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">110.0</td><td colspan="1" rowspan="1">112.0</td><td colspan="1" rowspan="1">49.0</td><td colspan="1" rowspan="1">45.2</td><td colspan="1" rowspan="1">94.0</td><td colspan="1" rowspan="1">60.8</td><td colspan="1" rowspan="1">54.7</td><td colspan="1" rowspan="1">81.3</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">93.0</td><td colspan="1" rowspan="1">81.25 (45.20–112.00)</td></tr><tr><td colspan="1" rowspan="1">Differed from trial inclusion criteria,<xref ref-type="bibr" rid="bib5"><sup>5</sup></xref><italic toggle="yes">n</italic> (%)</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">9 (81.82)</td></tr><tr><td colspan="1" rowspan="1"> NSAA &lt; 16</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">3 (27.27)</td></tr><tr><td colspan="1" rowspan="1"> TTR &gt; 5 s</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">5 (45.45)</td></tr><tr><td colspan="1" rowspan="1"> NSAA &gt; 29</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">1 (9.09)</td></tr><tr><td colspan="1" rowspan="1"> Corticosteroid-naive status</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">6 (54.54)</td></tr><tr><td colspan="1" rowspan="1"> Exon-skipping therapy</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">2 (18.18)</td></tr><tr><td colspan="1" rowspan="1"> Severe behavioral concerns</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">2 (18.18)</td></tr><tr><td colspan="1" rowspan="1"> Comorbid medical conditions</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">X<xref ref-type="table-fn" rid="tblfn3">c</xref></td><td colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">1 (9.09)</td></tr></tbody></table><table-wrap-foot><fn><p>N/A, not available; NSAA, North Star Ambulatory Assessment; TTR, time to rise; 10MWR, 10 m walk/run; 4SC, four-stair climb; 100MWR, 100 m walk/run.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn1"><label>a</label><p id="ntpara0020">Chronic corticosteroid use prior to initiation of label-recommended use.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn2"><label>b</label><p id="ntpara0025">Exon-skipping therapy was discontinued prior to delandistrogene moxeparvovec and not restarted.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn3"><label>c</label><p id="ntpara0030">Patient 10 had gastrostomy tube feeding dependence since infancy of unknown etiology following an extensive evaluation.</p></fn></table-wrap-foot></table-wrap></p><sec id="sec2.1"><title>Safety</title><p id="p0030">Nine of 11 patients (82%) experienced ≥1 side effect (<xref ref-type="supplementary-material" rid="mmc1">Table S1</xref>). These included mild gastrointestinal symptoms (7/11) and liver enzyme abnormalities (4/11). Two of the four patients with liver enzyme abnormalities met acute liver injury (ALI) criteria, defined as gamma-glutamyl transferase (GGT) &gt;3-fold the upper limit of normal (ULN), per pivotal trial and manufacturer standards.<xref ref-type="bibr" rid="bib5"><sup>5</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib9"><sup>9</sup></xref> The 18% (2/11) ALI rate is analogous to the 19% seen in EMBARK.<xref ref-type="bibr" rid="bib5"><sup>5</sup></xref> Three patients had troponin I elevations at 7, 12, and 52 weeks post-gene transfer that peaked at 25- to 43-fold ULN (<xref ref-type="supplementary-material" rid="mmc1">Figure S1</xref>), exceeding the incidence reported in EMBARK<xref ref-type="bibr" rid="bib5"><sup>5</sup></xref> (2/63, 3%). Toxicities were treated with corticosteroid escalation in 4/11 patients (<xref ref-type="table" rid="tbl1">Tables 1</xref> and <xref ref-type="supplementary-material" rid="mmc1">S1</xref>; <xref ref-type="fig" rid="fig1">Figure 1</xref>), a higher frequency than in EMBARK<xref ref-type="bibr" rid="bib5"><sup>5</sup></xref> (10/63, 16%).<fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Clinical courses of patients with concurrent acute liver and cardiac toxicity</p><p>Liver function test values (alanine aminotransferase [ALT], aspartate aminotransferase [AST], gamma-glutamyl transferase [GGT], and total bilirubin) and troponin I values relative to the test’s upper limit of normal (ULN) following delandistrogene moxeparvovec infusion are plotted in the upper and middle images, respectively, for patients 7 (A) and 10 (B). The bottom images reflect immune modulation during the clinical course and in response to toxicities. The Children’s Hospital of Philadelphia clinical lab ULN values are as follows: ALT ≤ 30 U/L, AST ≤ 50 U/L, GGT ≤ 16 U/L, total bilirubin ≤ 1.4 mg/dL, and troponin I ≤ 0.03 ng/mL.</p></caption><graphic orientation="portrait" position="float" xlink:href="gr1.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig></p><p id="p0035">Two patients experienced the most marked toxicities (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Patients 7 and 10 had concurrent hepatic and cardiac toxicity patterns of injury. Temporal association of concurrent toxicity was most marked in patient 7, who developed liver enzyme abnormalities beginning at week 8 with a peak GGT 15-fold the ULN, aspartate transaminase (AST) 28-fold the ULN, alanine transaminase (ALT) 51-fold the ULN, and total bilirubin 3-fold the ULN, without evidence of synthetic dysfunction (<xref ref-type="fig" rid="fig1">Figure 1</xref>A; <xref ref-type="supplementary-material" rid="mmc1">Table S1</xref>), also meeting Hy’s law criteria commonly used to define drug-induced liver injury. Proximal with peak hepatotoxicity, patient 7’s troponin I levels peaked at 34-fold the ULN at week 9 (<xref ref-type="fig" rid="fig1">Figure 1</xref>A), which was treated with escalation of oral steroid dosing, with a positive effect. Patient 10 demonstrated a rising GGT beginning at week 4, peaking at 3.4 times the ULN at week 11, without major changes in AST/ALT or bilirubin from baseline, and did not meet Hy’s law criteria. Troponin I levels rose concurrently, initially peaking at 25-fold the ULN at week 16 (<xref ref-type="fig" rid="fig1">Figure 1</xref>B). This was treated with intravenous methylprednisolone (10 mg/kg for 3 days), with improvement. However, troponin I levels rebounded after corticosteroid taper and transiently reached 36-fold the ULN at week 18 before resolving without further intervention (<xref ref-type="fig" rid="fig1">Figure 1</xref>B). Neither patient exhibited clinical signs of cardiac dysfunction or echocardiographic changes during peak troponin I elevations. There were no clinical symptoms of myositis. In patient 7, cardiovascular magnetic resonance imaging (CMR) at week 51 demonstrated diffuse and focal fibrosis and mildly reduced left ventricular ejection fraction (53%). In patient 10, CMR at week 19 revealed mild diffuse fibrosis without systolic dysfunction. In addition to patients 7 and 10, troponin I elevation was noted in patient 9 at 52 weeks post-gene transfer, in the setting of a recent viral illness, and sustained at 54 weeks without echocardiographic abnormalities; CMR evaluation 16 months post-vector showed normal left ventricular ejection fraction (LVEF) (63%) with mild diffuse fibrosis. None of the three patients had a baseline CMR for comparison.</p></sec><sec id="sec2.2"><title>Motor outcomes</title><p id="p0040">All 11 patients demonstrated statistically significant improvements in NSAA scores, with median gains of 3.5 (<italic toggle="yes">p</italic> = 0.0004) and 4 (<italic toggle="yes">p</italic> &lt; 0.0001) points at 6 and 12 months, respectively (<xref ref-type="fig" rid="fig2">Figure 2</xref>A). Timed function testing also showed statistically significant improvements (<xref ref-type="fig" rid="fig2">Figures 2</xref>B–2E). Sub-cohort analysis demonstrated statistically significant improvements from baseline in steroid-naive patients at 9 months by NSAA and 100 m walk/run (100MWR) at 12 months (mixed effects, two-way, matched ANOVA with Sidak’s multiple comparisons test, <italic toggle="yes">p</italic> = 0.0231 and <italic toggle="yes">p</italic> = 0.0247, respectively), raising the possibility that improvements in motor function seen in early real-world data may be due to gene therapy and/or steroid initiation in previously naive patients. Creatine kinase (CK; <xref ref-type="supplementary-material" rid="mmc1">Figure S1</xref>) and cystatin-C levels were initially obtained at the discretion of individual providers and later incorporated into standardized monitoring (<xref ref-type="supplementary-material" rid="mmc1">Table S3</xref>), making the dataset insufficient for analysis.<fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Change in functional motor outcomes up to 1 year following delandistrogene moxeparvovec</p><p>Median change from baseline is plotted for (A) North Star Ambulatory Assessment (NSAA) total score (<italic toggle="yes">n</italic> = 11) and timed function tests: (B) time to rise (TTR; <italic toggle="yes">n</italic> = 10, 1 patient excluded due to lack of cooperation at baseline), (C) 10 m walk/run (10MWR; <italic toggle="yes">n</italic> = 11), (D) four-stair climb (4SC; <italic toggle="yes">n</italic> = 11), and (E) 100 m walk/run (100MWR; <italic toggle="yes">n</italic> = 9: 2 patients excluded due to no baseline time). The whole patient cohort is represented by the solid blue line with the min-max range represented by gray shading. The whole cohort was divided into two sub-cohorts based on chronic corticosteroid status prior to initiation of the label-recommended corticosteroids. The sub-cohort median change from baseline and interquartile range are plotted (black lines; corticosteroid exposed: white circles; corticosteroid naive: black circles). Whole patient cohort statistical analyses: (A, C, E) mixed effects, matched one-way ANOVA with Dunnet’s multiple comparisons test and (B and D) nonparametric Friedman ANOVA were used to determine statistically significant differences in the change from baseline at each time point for the whole cohort. (B and D) Matched data were not normally distributed, and missing values were imputed using the whole cohort median at the given time point. Multiple comparisons are plotted in blue on top. ∗<italic toggle="yes">p</italic> &lt; 0.05, ∗∗<italic toggle="yes">p</italic> &lt; 0.01, ∗∗∗<italic toggle="yes">p</italic> &lt; 0.001, and ∗∗∗∗<italic toggle="yes">p</italic> &lt; 0.0001. Sub-cohort statistical analyses: (A, C, and E) mixed effects, two-way, matched ANOVA with Sidak’s multiple comparisons test was used to determine statistically significant differences in the change from baseline between the steroid-exposed and steroid-naive sub-cohorts at each time point. Significant differences were not detected at any time point except for NSAA at 9 months (<italic toggle="yes">p</italic> = 0.0231, not plotted) and 100MWR at 12 months (<italic toggle="yes">p</italic> = 0.0247, not plotted). (B and D) Two-tailed Mann-Whitney tests were performed at each time point to determine significant differences between the steroid-exposed and steroid-naive cohorts. Resultant <italic toggle="yes">p</italic> values were then adjusted based on the number of individual comparisons. Significant differences were not observed at any time point for either outcome measure.</p></caption><graphic orientation="portrait" position="float" xlink:href="gr2.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig></p></sec></sec><sec id="sec3"><title>Discussion</title><p id="p0045">This study provides real-world data on the safety and motor outcomes of 11 baseline ambulatory patients with DMD, ages 4–6, 1 year following delandistrogene moxeparvovec. Although toxicity observations were generally consistent with pivotal trial data, we noted a greater incidence of clinically asymptomatic, albeit markedly elevated, troponin I elevation detected on our expanded clinical monitoring protocol. All toxicities were effectively managed with corticosteroids. Over 12 months, functional motor outcomes improved following delandistrogene moxeparvovec, though the impact of baseline corticosteroid exposure—controlled for in the clinical trial but not in real-world data—may confound results.</p><p id="p0050">Troponin I elevations were detected in 3 patients through routine lab monitoring per our institutional protocol, but this was not required by the label or pivotal trial protocol.<xref ref-type="bibr" rid="bib5"><sup>5</sup></xref> Though peripheral mononuclear cells were not assayed for reactivity to AAVrh74 peptides, the timing of lab abnormalities in patients 7 and 10 at 4–12 weeks post-gene transfer and their responsiveness to corticosteroids support that an adaptive cellular immune response against the AAV capsid may, in part, contribute to the underlying mechanism. While an anti-AAV capsid immune response resulting in cardiac toxicity has not been previously described, similar hepatocellular hepatotoxicity patterns (without routine troponin I monitoring) consistent with a capsid immune response are well documented in hemophilia AAV gene therapy<xref ref-type="bibr" rid="bib10"><sup>10</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib11"><sup>11</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib12"><sup>12</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib13"><sup>13</sup></xref> and have also been observed in patients with spinal muscular atrophy (SMA) treated with onasemnogene abeparvovec.<xref ref-type="bibr" rid="bib14"><sup>14</sup></xref> Interestingly, troponin I elevations have been observed in patients with SMA ∼4 weeks after onasemnogene abeparvovec<xref ref-type="bibr" rid="bib15"><sup>15</sup></xref> and ∼5 weeks after resamirigene bilparvovec in patients with X-linked myotubular myopathy<xref ref-type="bibr" rid="bib16"><sup>16</sup></xref> without an implicated etiology; among other possibilities, whether these observations may represent an early cellular immune response to AAV is unknown. Similarly unclear is whether a cellular immune response to AAV contributes to long-term tissue toxicity. Patients 7, 9, and 10 demonstrated cardiac fibrosis on CMR within 1 year post-gene transfer, but the absence of baseline studies and limited CMR data in young patients with DMD<xref ref-type="bibr" rid="bib17"><sup>17</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib18"><sup>18</sup></xref> precludes causal conclusions. Only patients with troponin I elevations, i.e., patients 7, 9, and 10, had CMR in this cohort. Among the remaining 8 patients, 8 had normal echocardiograms at 1 year. The long-term cardiac effects of delandistrogene moxeparvovec are unknown but are of considerable interest. While EMBARK abstract-presented data (mean age: 5.9 years) showed no significant differences in left ventricular ejection fraction or myocardial strain metrics after 2 years,<xref ref-type="bibr" rid="bib19"><sup>19</sup></xref> emerging preclinical data suggest that micro-dystrophin overexpression may provoke cardiomyopathy<xref ref-type="bibr" rid="bib20"><sup>20</sup></xref> and cardiac inflammation.<xref ref-type="bibr" rid="bib21"><sup>21</sup></xref> Our findings support the cardiac monitoring approach proposed by the ACTION Duchenne network<xref ref-type="bibr" rid="bib22"><sup>22</sup></xref> and emphasize the importance of long-term follow-up to determine cardiac outcomes.</p><p id="p0055">In terms of motor function, the cohort demonstrated statistically significant improvements in NSAA scores and timed function testing after treatment. Multiple confounding factors limit interpretation. Nine patients did not meet EMBARK eligibility,<xref ref-type="bibr" rid="bib5"><sup>5</sup></xref> limiting comparison to trial data. Six patients were corticosteroid naive and initiated steroids—which have well-established benefits in DMD<xref ref-type="bibr" rid="bib23"><sup>23</sup></xref>—with gene therapy, complicating attribution of motor gains. Corticosteroids have well-established benefits in DMD.<xref ref-type="bibr" rid="bib23"><sup>23</sup></xref> Thus, it is unclear whether observed improvements were due to gene therapy, corticosteroids, or both. Additionally, motor improvements may partly reflect the natural history of early ambulatory DMD, where skill acquisition is expected.<xref ref-type="bibr" rid="bib24"><sup>24</sup></xref> Further, nearly half of patients had comorbid autism spectrum disorder and/or attention-deficit hyperactivity disorder, which can lower motor testing performance.<xref ref-type="bibr" rid="bib25"><sup>25</sup></xref> Thus, low baseline scores may reflect limited cooperation rather than disease severity, potentially inflating apparent treatment responses due to improved participation over time. Lastly, neither examiners nor patients were blinded to treatment. Nonetheless, despite lower baseline functional scores than the EMBARK cohort,<xref ref-type="bibr" rid="bib5"><sup>5</sup></xref> all patients in our study demonstrated motor function improvements relative to their own baseline (<xref ref-type="supplementary-material" rid="mmc1">Figure S2</xref>). Long-term motor outcomes remain unknown. Functional stabilization at year 4 was seen in participants 4–8 years who received a higher dose (2.0 × 10<sup>14</sup> vg/kg) of the vector<xref ref-type="bibr" rid="bib26"><sup>26</sup></xref> and at year 2 EMBARK follow-up.<xref ref-type="bibr" rid="bib27"><sup>27</sup></xref></p><p id="p0060">In summary, we observed gene-transfer-related side effects at higher rates than EMBARK data<xref ref-type="bibr" rid="bib5"><sup>5</sup></xref> that were corticosteroid responsive and emerged 6–12 weeks post-gene transfer. The majority of toxicities were consistent with an anti-capsid cellular immune response pattern, though cardiac toxicity from this mechanism has not been previously reported. Year 1 motor improvements are encouraging, but careful interpretation, given the potential confounding effects from our cohort, is necessary. The generalizability of the motor and safety outcomes reported herein in ambulatory patients with DMD is uncertain. These findings cannot be extrapolated to older, non-ambulatory patients, for whom limited efficacy data are available and whose greater comorbidities may increase susceptibility to AAV-associated toxicity, including two reported mortality events from hepatotoxicity following delandistrogene moxeparvovec administration.<xref ref-type="bibr" rid="bib28"><sup>28</sup></xref> Long-term follow-up is required to determine the significance of early toxicities and sustained motor outcomes.</p></sec><sec id="sec4"><title>Materials and methods</title><p id="p0065">Data were extracted from the clinical chart at the Children’s Hospital of Philadelphia (CHOP). Patients were followed per our institutional monitoring protocol (<xref ref-type="supplementary-material" rid="mmc1">Table S2</xref>), which expanded on-label recommendations to monitor for emerging AAV toxicities.<xref ref-type="bibr" rid="bib8"><sup>8</sup></xref> The study was reviewed and deemed exempt by the CHOP institutional review board. Patients without motor function scores at baseline (due to patient cooperation or injury; <italic toggle="yes">n</italic> = 1 for TTR, <italic toggle="yes">n</italic> = 2 for 100MWR) were excluded from analysis. Baseline-corrected motor function parameter distribution was determined using the Shapiro-Wilk test prior to analysis. The specific statistical testing is noted in the figure legends. Data were analyzed using GraphPad Prism.</p></sec><sec id="sec5" sec-type="data-availability"><title>Data and code availability</title><p id="p0070">De-identified data that support the findings of this study are not openly available due to patient confidentiality and may be available from the corresponding authors upon request.</p></sec><sec id="sec6"><title>Acknowledgments</title><p id="p0075">The authors would like to thank the Cell and Gene Therapy Collaborative at the Children’s Hospital of Philadelphia.</p></sec><sec id="sec7"><title>Author contributions</title><p id="p0080">D.J.K., J.C.S., S.M., S.E.M., and L.A.G. conceptualized the study. D.J.K., J.C.S., S.W.Y., C.A.W.-W., B.J.S.-J., S.E.M., and L.A.G. designed the study. D.J.K., T.S., and J.C.S. collected the data. D.J.K., J.C.S., and S.G.D. performed the analysis, and all authors interpreted the data. T.L.K., A.O., B.J.S.-J., A.T.W., J.F.B., S.W.Y., T.D., K.M.L., O.H.M., C.A.W.-W., K.Y.L., S.E.M., and L.A.G. contributed to the standardized monitoring protocol. D.J.K., S.E.M., and L.A.G. wrote the paper, and all the authors edited the manuscript.</p></sec><sec id="sec8" sec-type="COI-statement"><title>Declaration of interests</title><p id="p0085">A.T.W. has received research support from Sarepta Therapeutics and Pfizer. J.F.B. has served as a consultant for AveXis/Novartis, Biogen, Dyne Therapeutics, Edgewise Therapeutics, FibroGen, Genentech, Momenta/Janssen, NS Pharma, Pfizer, PTC Therapeutics, Sarepta Therapeutics, Scholar Rock Holding Corp, and Takeda and as a site investigator for research studies for Alexion Pharmaceuticals, Astellas, AveXis/Novartis, Biogen, Biohaven, Dyne Therapeutics, FibroGen, Genentech, ML Bio Solutions, Pfizer, PTC Therapeutics, Sarepta Therapeutics, and Scholar Rock Holding Corp. S.E.M. has served on advisory boards for Sarepta Therapeutics and has received research support from Sarepta Therapeutics, Dyne Therapeutics, Pfizer, and Genentech/Roche. C.A.W.-W. has served on an advisory board for Sarepta Therapeutics. L.A.G. is on the scientific advisory board of Form Bio, is a consultant for CSL Behring and Pfizer, and received licensing fees from Spark Therapeutics/F. Hoffman-La Roche AG.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation id="sref1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mercuri</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bönnemann</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Muntoni</surname><given-names>F.</given-names></name></person-group><article-title>Muscular dystrophies</article-title><source>Lancet</source><volume>394</volume><year>2019</year><fpage>2025</fpage><lpage>2038</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(19)32910-1</pub-id><pub-id pub-id-type="pmid">31789220</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation id="sref2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Byrne</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Flanigan</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Matesanz</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Finkel</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Waldrop</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>D’Ambrosio</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>N.E.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Bönnemann</surname><given-names>C.</given-names></name><name name-style="western"><surname>Carrig</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Current Clinical Applications of AAV-mediated Gene Therapy</article-title><source>Mol. Ther.</source><volume>33</volume><year>2025</year><fpage>2479</fpage><lpage>2516</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2025.04.045</pub-id><pub-id pub-id-type="pmid">40329530</pub-id><pub-id pub-id-type="pmcid">PMC12172329</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation id="sref3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramos</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chamberlain</surname><given-names>J.S.</given-names></name></person-group><article-title>Gene Therapy for Duchenne muscular dystrophy</article-title><source>Expert Opin. Orphan Drugs</source><volume>3</volume><year>2015</year><fpage>1255</fpage><lpage>1266</lpage><pub-id pub-id-type="doi">10.1517/21678707.2015.1088780</pub-id><pub-id pub-id-type="pmid">26594599</pub-id><pub-id pub-id-type="pmcid">PMC4651452</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation id="sref4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mendell</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Shieh</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Sahenk</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lehman</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Lowes</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Reash</surname><given-names>N.F.</given-names></name><name name-style="western"><surname>Iammarino</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Alfano</surname><given-names>L.N.</given-names></name><name name-style="western"><surname>Sabo</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy</article-title><source>Front. Cell Dev. Biol.</source><volume>11</volume><year>2023</year><object-id pub-id-type="publisher-id">1167762</object-id><pub-id pub-id-type="doi">10.3389/fcell.2023.1167762</pub-id><pub-id pub-id-type="pmcid">PMC10366687</pub-id><pub-id pub-id-type="pmid">37497476</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation id="sref5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mendell</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Muntoni</surname><given-names>F.</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Mercuri</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Ciafaloni</surname><given-names>E.</given-names></name><name name-style="western"><surname>Komaki</surname><given-names>H.</given-names></name><name name-style="western"><surname>Leon-Astudillo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nascimento</surname><given-names>A.</given-names></name><name name-style="western"><surname>Proud</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schara-Schmidt</surname><given-names>U.</given-names></name><etal/></person-group><article-title>AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial</article-title><source>Nat. Med.</source><volume>31</volume><year>2025</year><fpage>332</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1038/s41591-024-03304-z</pub-id><pub-id pub-id-type="pmid">39385046</pub-id><pub-id pub-id-type="pmcid">PMC11750718</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation id="sref6" publication-type="other"><person-group person-group-type="author"><collab>US Food and Drug Administration</collab></person-group><article-title>FDA approves first gene therapy for treatment of certain patients with Duchenne muscular dystrophy [media release]</article-title><ext-link ext-link-type="uri" id="intref0015" xlink:href="https://www.fda.gov" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.fda.gov</ext-link><year>2023</year></element-citation></ref><ref id="bib7"><label>7</label><element-citation id="sref7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mingozzi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Maus</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Hui</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Sabatino</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Rasko</surname><given-names>J.E.J.</given-names></name><name name-style="western"><surname>Ragni</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Manno</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Sommer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H.</given-names></name><etal/></person-group><article-title>CD8+ T-cell responses to adeno-associated virus capsid in humans</article-title><source>Nat. Med.</source><volume>13</volume><year>2007</year><fpage>419</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1038/nm1549</pub-id><pub-id pub-id-type="pmid">17369837</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation id="sref8" publication-type="other"><person-group person-group-type="author"><collab>US Food and Drug Administration</collab></person-group><article-title>ELEVIDYS package insert</article-title><ext-link ext-link-type="uri" id="intref0020" xlink:href="https://www.fda.gov" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.fda.gov</ext-link><year>2024</year></element-citation></ref><ref id="bib9"><label>9</label><element-citation id="sref9" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Proud</surname><given-names>C.</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Mercuri</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Muntoni</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zaidman</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Dharia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mason</surname><given-names>S.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Palatinsky</surname><given-names>E.</given-names></name><etal/></person-group><part-title>Long-term safety and tolerability of delandistrogene moxeparvovec in Duchenne muscular dystrophy: phase 1 to phase 3 clinical trials</part-title><source>Presented at the World Muscle Society 2024 Annual Congress, Prague, Czechia</source><year>2024</year></element-citation></ref><ref id="bib10"><label>10</label><element-citation id="sref10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nathwani</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Tuddenham</surname><given-names>E.G.D.</given-names></name><name name-style="western"><surname>Rangarajan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rosales</surname><given-names>C.</given-names></name><name name-style="western"><surname>McIntosh</surname><given-names>J.</given-names></name><name name-style="western"><surname>Linch</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Chowdary</surname><given-names>P.</given-names></name><name name-style="western"><surname>Riddell</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pie</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Harrington</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Adenovirus-associated virus vector-mediated gene transfer in hemophilia B</article-title><source>N. Engl. J. Med.</source><volume>365</volume><year>2011</year><fpage>2357</fpage><lpage>2365</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1108046</pub-id><pub-id pub-id-type="pmid">22149959</pub-id><pub-id pub-id-type="pmcid">PMC3265081</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation id="sref11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>George</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Monahan</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Eyster</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Ragni</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Croteau</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Rasko</surname><given-names>J.E.J.</given-names></name><name name-style="western"><surname>Recht</surname><given-names>M.</given-names></name><name name-style="western"><surname>Samelson-Jones</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>MacDougall</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A</article-title><source>N. Engl. J. Med.</source><volume>385</volume><year>2021</year><fpage>1961</fpage><lpage>1973</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2104205</pub-id><pub-id pub-id-type="pmid">34788507</pub-id><pub-id pub-id-type="pmcid">PMC8672712</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation id="sref12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>George</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Giermasz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rasko</surname><given-names>J.E.J.</given-names></name><name name-style="western"><surname>Samelson-Jones</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Ducore</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cuker</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Majumdar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Teitel</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant</article-title><source>N. Engl. J. Med.</source><volume>377</volume><year>2017</year><fpage>2215</fpage><lpage>2227</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1708538</pub-id><pub-id pub-id-type="pmid">29211678</pub-id><pub-id pub-id-type="pmcid">PMC6029626</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation id="sref13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manno</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Pierce</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Arruda</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Glader</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ragni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rasko</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Ozelo</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Hoots</surname><given-names>K.</given-names></name><name name-style="western"><surname>Blatt</surname><given-names>P.</given-names></name><name name-style="western"><surname>Konkle</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response</article-title><source>Nat. Med.</source><volume>12</volume><year>2006</year><fpage>342</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1038/nm1358</pub-id><pub-id pub-id-type="pmid">16474400</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation id="sref14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feldman</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Parsons</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Dutmer</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Veerapandiyan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hafberg</surname><given-names>E.</given-names></name><name name-style="western"><surname>Maloney</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mack</surname><given-names>C.L.</given-names></name></person-group><article-title>Subacute Liver Failure Following Gene Replacement Therapy for Spinal Muscular Atrophy Type 1</article-title><source>J. Pediatr.</source><volume>225</volume><year>2020</year><fpage>252</fpage><lpage>258.e1</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2020.05.044</pub-id><pub-id pub-id-type="pmid">32473148</pub-id><pub-id pub-id-type="pmcid">PMC10152980</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation id="sref15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friese</surname><given-names>J.</given-names></name><name name-style="western"><surname>Geitmann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Holzwarth</surname><given-names>D.</given-names></name><name name-style="western"><surname>Müller</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sassen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Baur</surname><given-names>U.</given-names></name><name name-style="western"><surname>Adler</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kirschner</surname><given-names>J.</given-names></name></person-group><article-title>Safety Monitoring of Gene Therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec -A Single Centre Experience</article-title><source>J. Neuromuscul. Dis.</source><volume>8</volume><year>2021</year><fpage>209</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.3233/JND-200593</pub-id><pub-id pub-id-type="pmid">33427694</pub-id><pub-id pub-id-type="pmcid">PMC8075402</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation id="sref16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shieh</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Kuntz</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Dowling</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Müller-Felber</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bönnemann</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Seferian</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Servais</surname><given-names>L.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Muntoni</surname><given-names>F.</given-names></name><name name-style="western"><surname>Blaschek</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial</article-title><source>Lancet Neurol.</source><volume>22</volume><year>2023</year><fpage>1125</fpage><lpage>1139</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(23)00313-7</pub-id><pub-id pub-id-type="pmid">37977713</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation id="sref17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Association of increased epicardial adipose tissue derived from cardiac magnetic resonance imaging with myocardial fibrosis in Duchenne muscular dystrophy: a clinical prediction model development and validation study in 283 participants</article-title><source>Quant. Imaging Med. Surg.</source><volume>14</volume><year>2024</year><fpage>736</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.21037/qims-23-790</pub-id><pub-id pub-id-type="pmid">38223028</pub-id><pub-id pub-id-type="pmcid">PMC10784074</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation id="sref18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hor</surname><given-names>K.N.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Al-Khalidi</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Cripe</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Raman</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Jefferies</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>O’Donnell</surname><given-names>R.</given-names></name><name name-style="western"><surname>Benson</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Mazur</surname><given-names>W.</given-names></name></person-group><article-title>Prevalence and distribution of late gadolinium enhancement in a large population of patients with Duchenne muscular dystrophy: effect of age and left ventricular systolic function</article-title><source>J. Cardiovasc. Magn. Reson.</source><volume>15</volume><year>2013</year><fpage>107</fpage><pub-id pub-id-type="doi">10.1186/1532-429X-15-107</pub-id><pub-id pub-id-type="pmid">24359596</pub-id><pub-id pub-id-type="pmcid">PMC3896985</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation id="sref19" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Walter</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vandenborne</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bourke</surname><given-names>J.</given-names></name><name name-style="western"><surname>Soslow</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mason</surname><given-names>S.</given-names></name><name name-style="western"><surname>Palatinsky</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wandel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>K.</given-names></name><name name-style="western"><surname>Reid</surname><given-names>C.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>A.P.</given-names></name><etal/></person-group><part-title>Cardiac MRI Outcomes in Patients with Duchenne Muscular Dystrophy Treated with Delandistrogene Moxeparvovec: Findings from EMBARK Part 1 [Abstract]</part-title><source>Presented at the Academy of Managed Care Pharmacy (AMCP) 2025 Congress, Houston, TX</source><year>2025</year></element-citation></ref><ref id="bib20"><label>20</label><element-citation id="sref20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hart</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.I.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Hammers</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Sweeney</surname><given-names>H.L.</given-names></name></person-group><article-title>Potential limitations of microdystrophin gene therapy for Duchenne muscular dystrophy</article-title><source>JCI Insight</source><volume>9</volume><year>2024</year><object-id pub-id-type="publisher-id">e165869</object-id><pub-id pub-id-type="doi">10.1172/jci.insight.165869</pub-id><pub-id pub-id-type="pmcid">PMC11382885</pub-id><pub-id pub-id-type="pmid">38713520</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation id="sref21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forand</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moog</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mougenot</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mégane Lemaitre</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Sevoz-Couche</surname><given-names>C.</given-names></name><name name-style="western"><surname>Guesmia</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Virtanen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Giordani</surname><given-names>L.</given-names></name><name name-style="western"><surname>Muchir</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pietri-Rouxel</surname><given-names>F.</given-names></name></person-group><article-title>Long-Term Dystrophin Replacement Therapy in Duchenne Muscular Dystrophy Causes Cardiac Inflammation</article-title><source>JACC. Basic Transl. Sci.</source><volume>10</volume><year>2025</year><fpage>759</fpage><lpage>782</lpage><pub-id pub-id-type="doi">10.1016/j.jacbts.2024.12.015</pub-id><pub-id pub-id-type="pmid">40562489</pub-id><pub-id pub-id-type="pmcid">PMC12230499</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation id="sref22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaufman</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Veerapandiyan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Soslow</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Wittlieb-Weber</surname><given-names>C.</given-names></name><name name-style="western"><surname>Esteso</surname><given-names>P.</given-names></name><name name-style="western"><surname>Olson</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Shih</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bansal</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gambetta</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Taking ACTION to detect myocarditis related to recombinant gene transfer therapy for Duchenne Muscular Dystrophy; Consensus recommendations for cardiac surveillance</article-title><source>J. Neuromuscul. Dis.</source><volume>12</volume><year>2025</year><fpage>173</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1177/22143602241303357</pub-id><pub-id pub-id-type="pmid">39973402</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation id="sref23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moxley</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Pandya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ciafaloni</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>K.</given-names></name></person-group><article-title>Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management</article-title><source>J. Child Neurol.</source><volume>25</volume><year>2010</year><fpage>1116</fpage><lpage>1129</lpage><pub-id pub-id-type="doi">10.1177/0883073810371004</pub-id><pub-id pub-id-type="pmid">20581335</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation id="sref24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muntoni</surname><given-names>F.</given-names></name><name name-style="western"><surname>Domingos</surname><given-names>J.</given-names></name><name name-style="western"><surname>Manzur</surname><given-names>A.Y.</given-names></name><name name-style="western"><surname>Mayhew</surname><given-names>A.</given-names></name><name name-style="western"><surname>Guglieri</surname><given-names>M.</given-names></name><name name-style="western"><surname>UK NorthStar Network</surname></name><name name-style="western"><surname>Sajeev</surname><given-names>G.</given-names></name><name name-style="western"><surname>Signorovitch</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>S.J.</given-names></name></person-group><article-title>Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy</article-title><source>PLoS One</source><volume>14</volume><year>2019</year><object-id pub-id-type="publisher-id">e0221097</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0221097</pub-id><pub-id pub-id-type="pmcid">PMC6719875</pub-id><pub-id pub-id-type="pmid">31479456</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation id="sref25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keselman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Glanzman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Thelen</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Prosser</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>McGuire</surname><given-names>J.</given-names></name><name name-style="western"><surname>Matesanz</surname><given-names>S.E.</given-names></name></person-group><article-title>Motor Function Testing Rates and Outcomes in Duchenne Muscular Dystrophy with Comorbid Autism and Attention-Deficit/Hyperactivity Disorder</article-title><source>Neuromuscul. Disord.</source><volume>48</volume><year>2025</year><object-id pub-id-type="publisher-id">105281</object-id><pub-id pub-id-type="doi">10.1016/j.nmd.2025.105281</pub-id><pub-id pub-id-type="pmid">39946777</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation id="sref26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mendell</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Sahenk</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lehman</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Lowes</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Reash</surname><given-names>N.F.</given-names></name><name name-style="western"><surname>Iammarino</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Alfano</surname><given-names>L.N.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Church</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shell</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trial</article-title><source>Muscle Nerve</source><volume>69</volume><year>2024</year><fpage>93</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1002/mus.27955</pub-id><pub-id pub-id-type="pmid">37577753</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation id="sref27" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Mendell</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Muntoni</surname><given-names>F.</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Mercuri</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Ciafaloni</surname><given-names>E.</given-names></name><name name-style="western"><surname>Komaki</surname><given-names>H.</given-names></name><name name-style="western"><surname>Leon-Astudillo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nascimento</surname><given-names>A.</given-names></name><name name-style="western"><surname>Proud</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schara-Schmidt</surname><given-names>U.</given-names></name><etal/></person-group><part-title>Long-Term Functional Outcomes, Safety, and Micro-dystrophin Expression Following Delandistrogene Moxeparvovec Treatment in DMD: EMBARK 2-Year Results</part-title><source>Presented at the Muscular Dystrophy Association 2025 Annual Conference, Dallas, TX</source><year>2025</year></element-citation></ref><ref id="bib28"><label>28</label><element-citation id="sref28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chamberlain</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Davidson</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>George</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Byrne</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Barrett</surname><given-names>D.</given-names></name></person-group><article-title>The future of gene therapy: Safer vectors, sharper focus: High-profile failures demand deep root cause analysis — but the transformative potential of AAV remains within reach if the field is willing to learn and evolve</article-title><source>Mol. Ther.</source><volume>33</volume><year>2025</year><fpage>4694</fpage><lpage>4695</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2025.08.029</pub-id><pub-id pub-id-type="pmid">40945512</pub-id><pub-id pub-id-type="pmcid">PMC12848144</pub-id></element-citation></ref></ref-list><sec id="appsec2" sec-type="supplementary-material"><title>Supplemental information</title><p id="p0095">
<supplementary-material content-type="local-data" id="mmc1" orientation="portrait" position="float"><caption><title>Document S1. Figures S1 and S2 and Tables S1–S3</title></caption><media orientation="portrait" position="float" xlink:href="mmc1.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/></supplementary-material>
<supplementary-material content-type="local-data" id="mmc2" orientation="portrait" position="float"><caption><title>Document S2. Article plus supplemental information</title></caption><media orientation="portrait" position="float" xlink:href="mmc2.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/></supplementary-material>
</p></sec><fn-group><fn fn-type="supplementary-material" id="appsec1"><p id="p0090">Supplemental information can be found online at <ext-link ext-link-type="uri" id="intref0010" xlink:href="https://doi.org/10.1016/j.ymthe.2025.10.007" xmlns:xlink="http://www.w3.org/1999/xlink">https://doi.org/10.1016/j.ymthe.2025.10.007</ext-link>.</p></fn></fn-group></back></article>